Sutro Biopharma (STRO) USD0.001
Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company. The Company is focused on using its integrated cell-free protein synthesis platform, XpressCF, to create a variety of protein therapeutics for cancer and autoimmune disorders. It focuses to design therapeutics using potent modalities, including cytokine-based immuno-oncology (I/O) therapeutics, antibody-drug conjugates (ADCs) and bispecific antibodies that are directed primarily against clinically validated targets. Its product candidate includes STRO-001 and STRO-002. STRO-001 is an ADC directed against the cancer target CD74, for patients with multiple myeloma and non-Hodgkin lymphoma (NHL). STRO-002 is an ADC directed against folate receptor-alpha (FolRa), for patients with ovarian and endometrial cancers. STRO-001 and STRO-002 are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody using its XpressCF Platform.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.